Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Non-Current Liabilities (2019 - 2021)

Historic Total Non-Current Liabilities for Nurix Therapeutics (NRIX) over the last 3 years, with Q3 2021 value amounting to $117.1 million.

  • Nurix Therapeutics' Total Non-Current Liabilities rose 1322.71% to $117.1 million in Q3 2021 from the same period last year, while for Aug 2021 it was $117.1 million, marking a year-over-year increase of 1322.71%. This contributed to the annual value of $105.2 million for FY2020, which is 10301.76% up from last year.
  • Per Nurix Therapeutics' latest filing, its Total Non-Current Liabilities stood at $117.1 million for Q3 2021, which was up 1322.71% from $119.0 million recorded in Q2 2021.
  • Over the past 5 years, Nurix Therapeutics' Total Non-Current Liabilities peaked at $125.7 million during Q1 2021, and registered a low of $51.8 million during Q4 2019.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $111.1 million (2020), whereas its average is $103.7 million.
  • Per our database at Business Quant, Nurix Therapeutics' Total Non-Current Liabilities skyrocketed by 10301.76% in 2020 and then skyrocketed by 1322.71% in 2021.
  • Quarter analysis of 3 years shows Nurix Therapeutics' Total Non-Current Liabilities stood at $51.8 million in 2019, then surged by 103.02% to $105.2 million in 2020, then increased by 11.25% to $117.1 million in 2021.
  • Its last three reported values are $117.1 million in Q3 2021, $119.0 million for Q2 2021, and $125.7 million during Q1 2021.